Semagacestat is a small molecule gamma-secretase inhibitor that was investigated as a potential disease-modifying therapy for Alzheimer’s disease. By targeting the gamma-secretase enzyme complex, the compound… Read more
Semagacestat is a small molecule gamma-secretase inhibitor that was investigated as a potential disease-modifying therapy for Alzheimer’s disease. By targeting the gamma-secretase enzyme complex, the compound was designed to reduce the production of amyloid-beta peptides, which are associated with the formation of neuritic plaques in the brain. In pharmaceutical and medicinal research, laboratories require high-quality reference standards of Semagacestat to support analytical testing and rigorous quality control. This category includes the parent drug as well as its related impurities and metabolites, which are essential for precise impurity profiling and the validation of analytical methods. Additionally, stable isotope-labelled compounds are available to serve as internal standards in mass spectrometry-based assays, facilitating accurate quantification and pharmacokinetic studies. These critical reference materials enable researchers to maintain consistency and reliability throughout their ongoing neurodegenerative disease research and analytical development programs.